Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.
Investment Led by Prominent Funds
The Series C financing round was led by Shanghai State-Owned Assets and Enterprises Comprehensive Reform Pilot Private Equity Fund Partnership Enterprise and ICBC Financial Asset Investment, with additional participation from Shanghai Healthcare Capital. This consortium of investors reflects confidence in Shanghai Pharma Health Commerce’s business model and market strategy.
Comprehensive Drug Supply Chain System
Shanghai Pharma Health Commerce prides itself on a complete integrated novel drug supply chain system. The company has established partnerships with over 300 pharmaceutical companies and has served more than 600 million patients. Additionally, it supports nearly 200 medical institutions, including more than 50 Class 3A Internet hospitals, highlighting its extensive reach and impact on healthcare delivery.-Fineline Info & Tech
